We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pharma Stocks Rebound as Trump Announces a 90-Day Pause on Tariffs
Read MoreHide Full Article
The stock market was on a roller coaster on April 9 amid the ongoing global trade war triggered by a new series of tariffs by the U.S. government. Most of the pharma bigwigs ended the trading session in green after bearing the brunt of investors’ skepticism earlier in the day on a plausible import tariff.
The share prices of Novo Nordisk (NVO - Free Report) , AbbVie (ABBV - Free Report) , Eli Lilly (LLY - Free Report) and AstraZeneca (AZN - Free Report) declined on Wednesday morning but gained thereafter, reflecting broader market optimism following President Trump's tweet that there would be a 90-day pause on reciprocal tariffs for non-retaliating countries.
Last week, Trump announced new tariffs on almost all trading partners in a move to reportedly boost domestic manufacturing. The so-called “reciprocal tariffs” included a 34% tax on imports from China and 20% on the European Union, among others, along with a 10% baseline tax on imports from all countries.
The stock markets around the world plunged earlier in the week on a likely slowdown around the corner with new tariffs in place. Nonetheless, a pause on the tariffs has somewhat alleviated these fears, and investors cheered the news.
Pharma Stocks Decline Earlier on Likely Tariff on Imports
The announcement made last week kept pharmaceutical imports free from the "reciprocal tariffs." However, earlier this week, President Trump disclosed plans to impose a new series of tariffs on pharmaceutical imports to encourage pharmaceutical companies to move their operations to the United States. He stated that the United States is a very big market, and the new tariffs will propel pharmaceutical companies to rush back to the country.
Per reports, the United States imports large amounts of finished drugs from other countries, and a significant chunk of this comes from China, which has retaliated with increased tariffs in response to Trump’s announcement.
The imports comprise finished drugs as well as active pharmaceutical ingredients (APIs) used to make drugs. Per Trump, the tariffs on pharmaceutical imports will force the companies to leave China.
Many big pharma companies have sizeable production units outside the country, and the imposition of tariffs will increase their costs, thereby shrinking margins. The tariffs will likely result in greater price hikes for cheaper generics than branded drugs.
In response, stocks like Novo Nordisk, Roche, Eli Lilly and AstraZeneca declined due to investor skepticism earlier in the day.
We note that companies like Novo Nordisk and Eli Lilly have already expanded their manufacturing capacity in the United States primarily to meet the increased demand for their lucrative obesity drugs.
Nonetheless, pharma companies will face a daunting task if and when the tariffs are formally imposed, as relocating a production process is a complex and expensive affair.
Image: Bigstock
Pharma Stocks Rebound as Trump Announces a 90-Day Pause on Tariffs
The stock market was on a roller coaster on April 9 amid the ongoing global trade war triggered by a new series of tariffs by the U.S. government. Most of the pharma bigwigs ended the trading session in green after bearing the brunt of investors’ skepticism earlier in the day on a plausible import tariff.
The share prices of Novo Nordisk (NVO - Free Report) , AbbVie (ABBV - Free Report) , Eli Lilly (LLY - Free Report) and AstraZeneca (AZN - Free Report) declined on Wednesday morning but gained thereafter, reflecting broader market optimism following President Trump's tweet that there would be a 90-day pause on reciprocal tariffs for non-retaliating countries.
Last week, Trump announced new tariffs on almost all trading partners in a move to reportedly boost domestic manufacturing. The so-called “reciprocal tariffs” included a 34% tax on imports from China and 20% on the European Union, among others, along with a 10% baseline tax on imports from all countries.
The stock markets around the world plunged earlier in the week on a likely slowdown around the corner with new tariffs in place. Nonetheless, a pause on the tariffs has somewhat alleviated these fears, and investors cheered the news.
Pharma Stocks Decline Earlier on Likely Tariff on Imports
The announcement made last week kept pharmaceutical imports free from the "reciprocal tariffs." However, earlier this week, President Trump disclosed plans to impose a new series of tariffs on pharmaceutical imports to encourage pharmaceutical companies to move their operations to the United States. He stated that the United States is a very big market, and the new tariffs will propel pharmaceutical companies to rush back to the country.
Per reports, the United States imports large amounts of finished drugs from other countries, and a significant chunk of this comes from China, which has retaliated with increased tariffs in response to Trump’s announcement.
The imports comprise finished drugs as well as active pharmaceutical ingredients (APIs) used to make drugs. Per Trump, the tariffs on pharmaceutical imports will force the companies to leave China.
Many big pharma companies have sizeable production units outside the country, and the imposition of tariffs will increase their costs, thereby shrinking margins. The tariffs will likely result in greater price hikes for cheaper generics than branded drugs.
In response, stocks like Novo Nordisk, Roche, Eli Lilly and AstraZeneca declined due to investor skepticism earlier in the day.
We note that companies like Novo Nordisk and Eli Lilly have already expanded their manufacturing capacity in the United States primarily to meet the increased demand for their lucrative obesity drugs.
Nonetheless, pharma companies will face a daunting task if and when the tariffs are formally imposed, as relocating a production process is a complex and expensive affair.
All these stocks currently carry a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.